ClinicalTrials.gg
Sign In
Not yet recruitingNCT06049485Updated Sep 22, 2023

Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research

An observational study in Follicular Lymphoma, sponsored by Power Life Sciences Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Power Life Sciences Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Historically, participation in medical studies is highly skewed towards particular demographic groups of people.

This research will invite several participants to gather a wide range of information on clinical trial experiences for follicular lymphoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of follicular lymphoma.

The data collected from this study will help improve future outcomes for all follicular lymphoma patients as well as those in under-represented demographic groups.

02

Conditions studied

  • Follicular Lymphoma

Browse trials for

Keywords

  • follicular lymphoma
03

In context

Lymphoma, Follicular

964 studies on the registry are indexed under Lymphoma, Follicular; 242 are open to participants now.

This study's planned enrollment of 500 is above the median of 200 across 106 observational studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Power Life Sciences Inc. is the lead sponsor of 111 studies on the registry; 109 are open to participants now.

Browse Power Life Sciences Inc. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with follicular lymphoma who are actively considering enrolling in a medical trial for the said condition, but have not yet completed enrollment and randomization phases.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 years of age or older
  • Patient has been diagnosed with follicular lymphoma
  • Patient has access to a home internet connection in order to provide regular updates through the course of the study

Exclusion criteria

Exclusion Criteria:

  • Women of childbearing potential without a negative pregnancy test; or women who are lactating.
  • Inability to provide written informed consent
  • Patients receiving any other investigational agents
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients who decide to enroll in a follicular lymphoma clinical research

    Time frame: 3 months

  2. Rate of patients who remain in a follicular lymphoma medical study to trial completion

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Gueiderikh A, Ung M, Lazarovici J, Danu A, Ghez D, Saleh K, Dragani M, Noel N, Bigenwald C, Willekens C, Ribrag V, Michot JM, Martin V. Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases. Cancer Radiother. 2023 Sep;27(5):370-375. doi: 10.1016/j.canrad.2023.04.004. Epub 2023 May 6. PubMed 37156711 ↗
  • Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009 Mar 10;27(8):1202-8. doi: 10.1200/JCO.2008.18.1495. Epub 2009 Feb 9. PubMed 19204203 ↗
  • Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):783-91. doi: 10.1016/j.ijrobp.2015.12.019. Epub 2015 Dec 17. PubMed 26972651 ↗

Study documents

  • Informed consent form · Sep 15, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.

Of 54 observational studies under Lymphoma, Follicular, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 120. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Sep 22, 2023
StartEst.
Oct 2024
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2026
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06049485
Lead sponsor
Power Life Sciences Inc.
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Oct 2024 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 22, 2023

Study contacts

Michael B Gill
Contact
bask@withpower.com
(415) 900-4227
Michael B Gill
study director · Power Life Sciences Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lymphoma, Follicular →

Other studies from this sponsor

Power Life Sciences Inc. →

Start the discussion